Compare TMCI & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMCI | EVMN |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 284.5M |
| IPO Year | 2021 | 2025 |
| Metric | TMCI | EVMN |
|---|---|---|
| Price | $5.19 | $7.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $6.17 | ★ $22.44 |
| AVG Volume (30 Days) | 298.9K | ★ 928.2K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $212,690,000.00 | $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.59 | ★ 85.71 |
| 52 Week Low | $1.17 | $4.94 |
| 52 Week High | $5.44 | $33.20 |
| Indicator | TMCI | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 61.43 | 57.47 |
| Support Level | $3.96 | $4.94 |
| Resistance Level | N/A | $13.35 |
| Average True Range (ATR) | 0.50 | 0.81 |
| MACD | 0.10 | 0.38 |
| Stochastic Oscillator | 87.62 | 70.28 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.